BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

IASO Biotherapeutics’ New Drug Application for Equecabtagene Autoleucel Accepted by Hong Kong Department of Health

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative ce...

February 17, 2025 | News

Akeso Initiates Phase 3 Trial in China for Cadonilimab as Consolidation Therapy in Advanced NSCLC

Akeso, Inc. announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION...

February 13, 2025 | News

AIM Vaccine Leads China's mRNA Innovation, Submits Breakthrough Shingles Vaccine for Clinical Trials

AIM Vaccine Co, a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA s...

February 12, 2025 | News

Bowtie, Gleneagles Hospital, and Pfizer Hong Kong Unite to Combat Migraine Misconceptions

Bowtie, Hong Kong's pioneering virtual insurer, has joined forces with Gleneagles Hospital Hong Kong and Pfizer Hong Kong to la...

February 10, 2025 | News

Akeso Completes Global Phase III Enrollment for Ivonescimab in Squamous NSCLC

Akeso, Inc. is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab...

February 06, 2025 | News

Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers

Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...

January 23, 2025 | News

Akeso Inc. Receives Milestone Payment from Sichuan Kelun for PD-L1 Antibody Tagitanlimab After China’s Regulatory Approval

Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their coll...

January 23, 2025 | News

Ascletis Pharma Reports Promising Results for ASC30 Oral Tablet in Obesity Treatment

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose ...

January 22, 2025 | News

HKUST Researchers Develop World's Smallest Multifunctional Biomedical Robot for Precision Diagnosis and Treatment

Researchers from the School of Engineering of the Hong Kong University of Science and Technology (HKUST) have successfully developed the world's ...

January 21, 2025 | News

Guangzhou Fermion Partners with Simcere to Advance Clinical-Stage SSTR4 Agonist for Pain Management

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment ass...

January 20, 2025 | News

Eyebright Medical Secures NMPA Approval for Loong Crystal PR, a Cutting-Edge Solution for Myopia Correction

Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries coll...

January 08, 2025 | News

HKSH Cancer Centre Hosts Sixth Symposium on Cancer Management, Celebrates One Year of Proton Therapy Milestones

HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on 12 December 2024 at ...

January 03, 2025 | News

Sanofi Acquires Greater China Rights for Aficamten from CORXEL, Expanding HCM Treatment Reach

Cytokinetics, Incorporated announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL...

December 20, 2024 | News

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older...

December 20, 2024 | News

Stay Connected